Lauren A Eberly

Dr. Lauren A Eberly


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
LELauren A Eberly
Lauren A Eberly
LYLin Yang
Lin Yang
NENwamaka D. Eneanya
Nwamaka D. Eneanya
UEUtibe Essien
Utibe Essien
HJHoward Julien
Howard Julien
SASrinath Adusumalli
Srinath Adusumalli
Diabetes is significantly associated with development of cardiovascular and kidney disease in the US.1,2 Sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease kidney glucose reabsorption and thereby increase urinary glucose excretion and improve in blood glucose levels.3 In addition to improved glycemic control, since publication of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus (EMPA-REG) in 2015,4 studies have demonstrated substantial classwide cardioprotective and kidney-protective effect of this medication.5 Among patients with type 2 diabetes at high risk for cardiovascular events, SGLT2 inhibitor use has been shown to significantly reduce death from cardiovascular causes and to lower the risk of hospitalization for heart failure and progression of kidney disease.4,6 Rates of worsening heart failure or cardiovascular death are lower among patients with heart failure who are treated with dapagliflozin and empagliflozin regardless of diabetes diagnosis.7,8 Treatment with dapagliflozin reduces adverse kidney events and decreases mortality among patients with chronic kidney disease (CKD).9 Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.

17 December 2021 in JAMA Health Forum
Verified
Journal Article
Open access
PDF file
LELauren A Eberly
Lauren A Eberly
LYLin Yang
Lin Yang
UEUtibe R. Essien
Utibe R. Essien
NENwamaka D. Eneanya
Nwamaka D. Eneanya
HJHoward M. Julien
Howard M. Julien
SASrinath Adusumalli
Srinath Adusumalli
In the US, cardiovascular disease is the leading cause of mortality and morbidity among patients with type 2 diabetes (T2D).1 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recommended treatment option for glycemic control in patients with diabetes, have recently emerged as a cardioprotective therapy.2 Multiple large randomized clinical trials3-5 have shown GLP-1 RAs prevent cardiovascular events among patients with T2D, particularly patients with established atherosclerotic cardiovascular disease (ASCVD). These data have prompted a paradigm shift to utilize these agents not only for glycemic control, but for cardiovascular risk reduction. The American Diabetes Association updated guidelines and the American College of Cardiology expert consensus statement6 now recommend a GLP-1 RA with demonstrated cardiovascular benefit for patients with diabetes and established or at very high risk for ASCVD.

14 November 2023 in Circulation
Verified
Journal Article
Closed access
SKSameed Ahmed M. Khatana
Sameed Ahmed M. Khatana
LELauren A Eberly
Lauren A Eberly
ANAshwin S. Nathan
Ashwin S. Nathan
PGPeter W. Groeneveld
Peter W. Groeneveld
BACKGROUND: Climate change is causing an increase in extreme heat. Individuals with cardiovascular disease are at high risk of heat-related adverse health effects. How the burden of extreme heat–associated cardiovascular deaths in the United States will change with the projected rise in extreme heat is unknown. METHODS: We obtained data on cardiovascular deaths among adults and the number of extreme heat days (maximum heat index ≥90 °F [32.2 °C]) in each county in the contiguous United States from 2008 to 2019. Based on representative concentration pathway trajectories that model greenhouse gas emissions and shared socioeconomic pathways (SSP) that model future socioeconomic scenarios and demographic projections, we obtained county-level projected numbers of extreme heat days and populations under 2 scenarios for the midcentury period 2036 to 2065: SSP2-4.5 (representing demographic projections from a “middle-of-the-road” socioeconomic scenario and an intermediate increase in emissions) and SSP5-8.5 (demographic projections in an economy based on “fossil-fueled development” and a large increase in emissions). The association of cardiovascular mortality with extreme heat was estimated with a Poisson fixed-effects model. Using estimates from this model, the projected number of excess cardiovascular deaths associated with extreme heat was calculated. RESULTS: Extreme heat was associated with 1651 (95% CI, 921–2381) excess cardiovascular deaths per year from 2008 to 2019. By midcentury, extreme heat is projected to be associated with 4320 (95% CI, 2369–6272) excess deaths annually, which is an increase of 162% (95% CI, 142–182) under SSP2-4.5, and 5491 (95% CI, 3011–7972) annual excess deaths, which is an increase of 233% (95% CI, 206–259) under SSP5-8.5. Elderly adults are projected to have a 3.5 (95% CI, 3.2–3.8) times greater increase in deaths in the SSP2-4.5 scenario compared with nonelderly adults. Non-Hispanic Black adults are projected to have a 4.6 (95% CI, 2.8–6.4) times greater increase compared with non-Hispanic White adults. The projected change in deaths was not statistically significantly different for other race and ethnicity groups or between men and women. CONCLUSIONS: By midcentury, extreme heat is projected to be associated with a significantly greater burden of excess cardiovascular deaths in the contiguous United States.

17 June 2019 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
LELauren A Eberly
Lauren A Eberly
CRChristian Rusangwa
Christian Rusangwa
LNLoise Ng'ANg'A
Loise Ng'ANg'A
CNClaire C Neal
Claire C Neal
JMJean Paul Mukundiyukuri
Jean Paul Mukundiyukuri
GBGene Bukhman
Gene Bukhman
Background Integrated clinical strategies to address non-communicable disease (NCDs) in sub-Saharan Africa have largely been directed to prevention and treatment of common conditions at primary health centres. This study examines the cost of organising integrated nurse-driven, physician-supervised chronic care for more severe NCDs at an outpatient specialty clinic associated with a district hospital in rural Rwanda. Conditions addressed included type 1 and type 2 diabetes, chronic respiratory disease, heart failure and rheumatic heart disease. Methods A retrospective costing analysis was conducted from the facility perspective using data from administrative sources and the electronic medical record systems of Butaro District Hospital in rural Rwanda. We determined initial start-up and annual operating financial cost of the Butaro district advanced NCD clinic for the fiscal year 2013–2014. Per-patient annual cost by disease category was determined. Results A total of US$47 976 in fixed start-up costs was necessary to establish a new advanced NCD clinic serving a population of approximately 300 000 people (US$0.16 per capita). The additional annual operating cost for this clinic was US$68 975 (US$0.23 per capita) to manage a 632-patient cohort and provide training, supervision and mentorship to primary health centres. Labour comprised 54% of total cost, followed by medications at 17%. Diabetes mellitus had the highest annual cost per patient (US$151), followed by heart failure (US$104), driven primarily by medication therapy and laboratory testing. Conclusions This is the first study to evaluate the costs of integrated, decentralised chronic care for some severe NCDs in rural sub-Saharan Africa. The findings show that these services may be affordable to governments even in the most constrained health systems.

14 July 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LELauren A Eberly
Lauren A Eberly
HJHoward Julien
Howard Julien
ESEugenia C. South
Eugenia C. South
AVAtheendar Venkataraman
Atheendar Venkataraman
ANAshwin S. Nathan
Ashwin S. Nathan
SKSameed Ahmed M. Khatana
Sameed Ahmed M. Khatana
Background: Violent crime has recently increased in many major metropolitan cities in the United States. Prior studies suggest an association between neighborhood crime levels and cardiovascular disease, but many have been limited by cross‐sectional designs. We investigated whether longitudinal changes in violent crime rates are associated with changes in cardiovascular mortality rates at the community level in one large US city‐Chicago, IL. Methods and Results: Chicago is composed of 77 community areas. Age‐adjusted mortality rates by community area for cardiovascular disease, stroke, and coronary artery disease from 2000 to 2014, aggregated at 5‐year intervals, were obtained from the Illinois Department of Public Health Division of Vital Records. Mean total and violent crime rates by community area were obtained from the City of Chicago Police Data Portal. Using a 2‐way fixed effects estimator, we assessed the association between longitudinal changes in violent crime and cardiovascular mortality rates after accounting for changes in demographic and economic variables and secular time trends at the community area level from 2000 to 2014. Between 2000 and 2014, the median violent crime rate in Chicago decreased from 3620 per 100 000 (interquartile range [IQR], 2256, 7777) in the 2000 to 2004 period to 2390 (IQR 1507, 5745) in the 2010 to 2014 period ( P =0.005 for trend). In the fixed effects model a 1% decrease in community area violent crime rate was associated with a 0.21% (95% CI, 0.09–0.33) decrease in cardiovascular mortality rates ( P =<0.001) and a 0.19% (95% CI, 0.04–0.33) decrease in coronary artery disease mortality rates ( P =0.01). There was no statistically significant association between change in violent crime and stroke mortality rates (−0.17% [95% CI, −0.42 to 0.08; P =0.18]). Conclusions: From 2000 to 2014, a greater decrease in violent crime at the community area level was associated with a greater decrease in cardiovascular and coronary artery disease mortality rates in Chicago. These findings add to the growing evidence of the impact of the built environment on health and implicate violent crime exposure as a potential social determinant of cardiovascular health. Targeted investment in communities to decrease violent crime may improve community cardiovascular health.

3 September 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SKSameed Ahmed M. Khatana
Sameed Ahmed M. Khatana
JSJonathan J. Szeto
Jonathan J. Szeto
LELauren A Eberly
Lauren A Eberly
ANAshwin S. Nathan
Ashwin S. Nathan
JPJagadeesh Puvvula
Jagadeesh Puvvula
ACAimin Chen
Aimin Chen
In the US, due to anthropogenic greenhouse gas emissions, extreme heat has increased substantially and is projected to increase further in the coming decades.1,2 Concurrently, extreme cold episodes are declining.3 Understanding how these changes along with demographic changes will affect the burden of temperature-related mortality is crucial to informing climate change policy efforts to improve population health.